Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03898180




Registration number
NCT03898180
Ethics application status
Date submitted
29/03/2019
Date registered
1/04/2019
Date last updated
22/07/2024

Titles & IDs
Public title
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Scientific title
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
Secondary ID [1] 0 0
MK-7902-011
Secondary ID [2] 0 0
7902-011
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urothelial Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Bladder - transitional cell cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Pembrolizumab
Treatment: Drugs - Lenvatinib
Treatment: Drugs - Placebo for lenvatinib

Experimental: Pembrolizumab + Lenvatinib - Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue lenvatinib and participants who remain on treatment will receive open label pembrolizumab only, at the same dose and schedule (IV 200 mg on Day 1 of each 21-Day cycle for up to 35 cycles \[up to \~2 years\]).

Active comparator: Pembrolizumab + Placebo - Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years) PLUS placebo for lenvatinib via oral capsule QD until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue placebo and participants who remain on treatment will receive open label pembrolizumab only, at the same dose and schedule (IV 200 mg on Day 1 of each 21-Day cycle for up to 35 cycles \[up to \~2 years\]).


Treatment: Other: Pembrolizumab
IV infusion

Treatment: Drugs: Lenvatinib
oral capsule

Treatment: Drugs: Placebo for lenvatinib
oral capsule
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
Up to ~25 months
Primary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to ~25 months
Secondary outcome [1] 0 0
Objective Response Rate (ORR)
Timepoint [1] 0 0
Up to ~25 months
Secondary outcome [2] 0 0
Duration of Response (DOR)
Timepoint [2] 0 0
Up to ~25 months
Secondary outcome [3] 0 0
Disease Control Rate (DCR)
Timepoint [3] 0 0
Up to ~25 months
Secondary outcome [4] 0 0
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Timepoint [4] 0 0
Baseline and Up to ~60 months
Secondary outcome [5] 0 0
Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Timepoint [5] 0 0
Up to ~60 months
Secondary outcome [6] 0 0
Number of Participants Who Experience an Adverse Event (AE)
Timepoint [6] 0 0
Up to ~25 months
Secondary outcome [7] 0 0
Number of Participants Who Discontinue Study Treatment Due to an AE
Timepoint [7] 0 0
Up to ~25 months

Eligibility
Key inclusion criteria
* Has a histologically or cytologically confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial carcinoma (UC) of the renal pelvis, ureter (upper urinary tract), bladder, or urethra.
* Has =1 measurable target lesion per RECIST 1.1 as assessed by the local site investigator/radiologist.
* Has provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated and adequate for Programmed Death-Ligand 1 (PD-L1) evaluation.
* Has received no prior systemic chemotherapy for advanced or metastatic UC with the following exceptions:
* Neoadjuvant (prior to surgery) platinum-based chemotherapy for treatment of muscle-invasive bladder cancer with recurrence >12 months from completion of the therapy is permitted.
* Adjuvant (following surgery) platinum-based chemotherapy following radical cystectomy, with recurrence >12 months from completion of the therapy, is permitted.
* Meets criteria for either option a or option b (below):
* a. Has a tumor(s) with PD-L1 combined positive score (CPS) =10 and is considered ineligible to receive cisplatin-based combination therapy, based on 1 of the following:
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 2 within 7 days prior to randomization
* National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Grade =2 audiometric hearing loss
* NCI CTCAE Version 4.0 Grade =2 peripheral neuropathy OR
* b. In the opinion of the investigator, is considered ineligible to receive any platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin) based on:
* ECOG PS of 2 within 7 days prior to randomization and =1 of the following:
* Documented visceral metastatic disease
* NCI CTCAE Version 4.0 Grade =2 audiometric hearing loss
* NCI CTCAE Version 4.0 Grade =2 peripheral neuropathy
* Other reason for the participant's being unable to receive both cisplatin and carboplatin safely. Additional criteria for platinum ineligibility will be considered and allowed on a case-by-case basis, following consultation with the Sponsor. Note: Participants considered ineligible for any platinum-based chemotherapy are eligible for this study regardless of their tumor PD-L1 status.
* Has ECOG PS 0, 1, or 2 within 7 days prior to randomization and a life expectancy of =3 months.
* Male participants are eligible to participate if they agree to the following during the treatment period and for =30 days after the last dose of pembrolizumab or lenvatinib/placebo:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR
* Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause as detailed below:
* Agrees to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
* A female participant is eligible to participate if she is not pregnant or breastfeeding and if she is not a WOCBP OR is a WOCBP and is using a contraceptive method that is highly effective (with a failure rate of <1% per year) with low user dependency, or is abstinent from heterosexual intercourse as her preferred and usual lifestyle during the intervention period and for =120 days post pembrolizumab or =30 days post lenvatinib/placebo.
* Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP =150/90 mm Hg at screening and no change in antihypertensive medications within 1 week prior to randomization.
* Has adequate organ function.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has disease that is suitable for local therapy administered with curative intent (e.g. chemotherapy and radiation for Stage 3 disease).
* Has tumor with any neuroendocrine or small cell component.
* Has a history of a gastrointestinal condition or procedure (e.g. gastric bypass, malabsorption) that, in the opinion of the investigator, may affect oral drug absorption.
* Has had major surgery within 3 weeks prior to the first dose of study treatment
* Has a pre-existing Grade =3 gastrointestinal or non-gastrointestinal fistula.
* Has radiographic evidence of major blood vessel invasion/infiltration, or has had clinically significant hemoptysis (=0.5 teaspoon of bright red blood) or tumor bleeding within 2 weeks prior to the first dose of study treatment.
* Has had significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of New York Heart Association (NYHA) >Class II congestive heart failure, unstable angina, myocardial infarction or cerebrovascular accident (CVA)/stroke, cardiac revascularization procedure, or cardiac arrhythmia associated with hemodynamic instability.
* Has known intolerance or severe hypersensitivity (Grade =3) to pembrolizumab or lenvatinib or any of their excipients
* Has received lenvatinib as monotherapy or in combination with a programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor or has previously been enrolled in a clinical study evaluating lenvatinib for bladder cancer, regardless of the treatment received.
* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor, indoleamine-pyrrole 2,3 dioxygenase (IDO1) inhibitor, or agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], OX 40, CD137), or any other antibody or drug targeting T-cell costimulatory pathways in the adjuvant or advanced/metastatic setting.
* Has received prior radiotherapy to a metastatic site without the use of chemotherapy radiosensitization within 3 weeks of the first dose of study treatment, with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks before the start of study treatment. Participants must have recovered from all radiation-related toxicities, and must not require corticosteroids.
* Has received a live vaccine within 30 days prior to the first dose of study treatment.
* In the investigator's judgment, has not recovered from toxicity or other complications from any major surgery prior to starting study treatment.
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
* Has history or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization.
* Has had an active malignancy (except locally advanced or metastatic UC) within the past 36 months. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) who have undergone potentially curative therapy are not excluded.
* Has a history of prostate cancer (T2NXMX or lower with Gleason score =7) treated with definitive intent (surgically or with radiation therapy) =1 year prior to study entry is acceptable, provided that the participant is considered prostate cancer-free.
* Has central nervous system (CNS) metastases, unless the participant has completed local therapy (e.g. whole brain radiation therapy, surgery, or radiosurgery) and has discontinued use of corticosteroids for this indication for =4 weeks before starting study treatment. Any signs (e.g. radiologic) or symptoms of CNS metastases must be stable for =4 weeks before starting study treatment.
* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e, with disease-modifying agents, corticosteroids, or immunosuppressive drugs).
* Has a history of (non-infectious) pneumonitis that required systemic steroids, or current pneumonitis.
* Has an active infection requiring systemic therapy.
* Has a known history of human immunodeficiency virus (HIV) infection.
* Has a known history of or is positive for active hepatitis B virus (HBV) or has active hepatitis C virus (HCV).
* Has active tuberculosis (TB).
* Is receiving hemodialysis.
* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and lenvatinib/placebo.
* Has had an allogeneic tissue/solid organ transplant.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/05/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/05/2024
Sample size
Target
Accrual to date
Final
487
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Macquarie University ( Site 0151) - North Ryde
Recruitment hospital [2] 0 0
Mater Misericordiae Ltd ( Site 0158) - South Brisbane
Recruitment hospital [3] 0 0
Monash Health ( Site 0160) - Clayton
Recruitment hospital [4] 0 0
Peninsula Health Frankston Hospital ( Site 0153) - Frankston
Recruitment hospital [5] 0 0
Austin Health-Austin Hospital ( Site 0154) - Heidelberg
Recruitment postcode(s) [1] 0 0
2109 - North Ryde
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3199 - Frankston
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Maine
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
South Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Virginia
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
Argentina
State/province [16] 0 0
Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Caba
Country [18] 0 0
Argentina
State/province [18] 0 0
Rio Negro
Country [19] 0 0
Argentina
State/province [19] 0 0
Santa Fe
Country [20] 0 0
Argentina
State/province [20] 0 0
Cordoba
Country [21] 0 0
Argentina
State/province [21] 0 0
Mendoza
Country [22] 0 0
Canada
State/province [22] 0 0
Ontario
Country [23] 0 0
Canada
State/province [23] 0 0
Quebec
Country [24] 0 0
China
State/province [24] 0 0
Beijing
Country [25] 0 0
China
State/province [25] 0 0
Chongqing
Country [26] 0 0
China
State/province [26] 0 0
Fujian
Country [27] 0 0
China
State/province [27] 0 0
Guangdong
Country [28] 0 0
China
State/province [28] 0 0
Heilongjiang
Country [29] 0 0
China
State/province [29] 0 0
Hubei
Country [30] 0 0
China
State/province [30] 0 0
Hunan
Country [31] 0 0
China
State/province [31] 0 0
Jiangsu
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
China
State/province [33] 0 0
Shanxi
Country [34] 0 0
China
State/province [34] 0 0
Xinjiang
Country [35] 0 0
China
State/province [35] 0 0
Zhejiang
Country [36] 0 0
Denmark
State/province [36] 0 0
Hovedstaden
Country [37] 0 0
Denmark
State/province [37] 0 0
Midtjylland
Country [38] 0 0
Denmark
State/province [38] 0 0
Nordjylland
Country [39] 0 0
Denmark
State/province [39] 0 0
Syddanmark
Country [40] 0 0
France
State/province [40] 0 0
Ain
Country [41] 0 0
France
State/province [41] 0 0
Alsace
Country [42] 0 0
France
State/province [42] 0 0
Bouches-du-Rhone
Country [43] 0 0
France
State/province [43] 0 0
Finistere
Country [44] 0 0
France
State/province [44] 0 0
Gironde
Country [45] 0 0
France
State/province [45] 0 0
Haute-Garonne
Country [46] 0 0
France
State/province [46] 0 0
Languedoc-Roussillon
Country [47] 0 0
France
State/province [47] 0 0
Loire-Atlantique
Country [48] 0 0
France
State/province [48] 0 0
Maine-et-Loire
Country [49] 0 0
France
State/province [49] 0 0
Meurthe-et-Moselle
Country [50] 0 0
France
State/province [50] 0 0
Pyrenees-Atlantiques
Country [51] 0 0
France
State/province [51] 0 0
Rhone
Country [52] 0 0
France
State/province [52] 0 0
Val-de-Marne
Country [53] 0 0
France
State/province [53] 0 0
Vendee
Country [54] 0 0
France
State/province [54] 0 0
Paris
Country [55] 0 0
Germany
State/province [55] 0 0
Baden-Wurttemberg
Country [56] 0 0
Germany
State/province [56] 0 0
Hessen
Country [57] 0 0
Germany
State/province [57] 0 0
Mecklenburg-Vorpommern
Country [58] 0 0
Germany
State/province [58] 0 0
Niedersachsen
Country [59] 0 0
Germany
State/province [59] 0 0
Nordrhein-Westfalen
Country [60] 0 0
Germany
State/province [60] 0 0
Schleswig-Holstein
Country [61] 0 0
Germany
State/province [61] 0 0
Hamburg
Country [62] 0 0
Hungary
State/province [62] 0 0
Bacs-Kiskun
Country [63] 0 0
Hungary
State/province [63] 0 0
Borsod-Abauj-Zemplen
Country [64] 0 0
Hungary
State/province [64] 0 0
Jasz-Nagykun-Szolnok
Country [65] 0 0
Hungary
State/province [65] 0 0
Vas
Country [66] 0 0
Hungary
State/province [66] 0 0
Budapest
Country [67] 0 0
Hungary
State/province [67] 0 0
Kaposvar
Country [68] 0 0
Israel
State/province [68] 0 0
Afula
Country [69] 0 0
Israel
State/province [69] 0 0
Ashdod
Country [70] 0 0
Israel
State/province [70] 0 0
Haifa
Country [71] 0 0
Israel
State/province [71] 0 0
Jerusalem
Country [72] 0 0
Israel
State/province [72] 0 0
Kfar Saba
Country [73] 0 0
Israel
State/province [73] 0 0
Petach-Tikwa
Country [74] 0 0
Israel
State/province [74] 0 0
Ramat Gan
Country [75] 0 0
Israel
State/province [75] 0 0
Tel Aviv
Country [76] 0 0
Israel
State/province [76] 0 0
Zerifin
Country [77] 0 0
Italy
State/province [77] 0 0
Lombardia
Country [78] 0 0
Italy
State/province [78] 0 0
Pordenone
Country [79] 0 0
Italy
State/province [79] 0 0
Bari
Country [80] 0 0
Italy
State/province [80] 0 0
Bologna
Country [81] 0 0
Italy
State/province [81] 0 0
Catania
Country [82] 0 0
Italy
State/province [82] 0 0
Milano
Country [83] 0 0
Italy
State/province [83] 0 0
Terni
Country [84] 0 0
Italy
State/province [84] 0 0
Verona
Country [85] 0 0
Japan
State/province [85] 0 0
Aomori
Country [86] 0 0
Japan
State/province [86] 0 0
Chiba
Country [87] 0 0
Japan
State/province [87] 0 0
Ehime
Country [88] 0 0
Japan
State/province [88] 0 0
Hokkaido
Country [89] 0 0
Japan
State/province [89] 0 0
Ibaraki
Country [90] 0 0
Japan
State/province [90] 0 0
Kanagawa
Country [91] 0 0
Japan
State/province [91] 0 0
Nara
Country [92] 0 0
Japan
State/province [92] 0 0
Saitama
Country [93] 0 0
Japan
State/province [93] 0 0
Yamaguchi
Country [94] 0 0
Japan
State/province [94] 0 0
Akita
Country [95] 0 0
Japan
State/province [95] 0 0
Nagasaki
Country [96] 0 0
Japan
State/province [96] 0 0
Osaka
Country [97] 0 0
Japan
State/province [97] 0 0
Tokushima
Country [98] 0 0
Japan
State/province [98] 0 0
Tokyo
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Jeonranamdo
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Kyonggi-do
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Taejon-Kwangyokshi
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Seoul
Country [103] 0 0
Netherlands
State/province [103] 0 0
Gelderland
Country [104] 0 0
Netherlands
State/province [104] 0 0
Limburg
Country [105] 0 0
Netherlands
State/province [105] 0 0
Noord-Brabant
Country [106] 0 0
Netherlands
State/province [106] 0 0
Overijssel
Country [107] 0 0
Netherlands
State/province [107] 0 0
Zuid-Holland
Country [108] 0 0
Netherlands
State/province [108] 0 0
Utrecht
Country [109] 0 0
Poland
State/province [109] 0 0
Dolnoslaskie
Country [110] 0 0
Poland
State/province [110] 0 0
Malopolskie
Country [111] 0 0
Poland
State/province [111] 0 0
Mazowieckie
Country [112] 0 0
Poland
State/province [112] 0 0
Slaskie
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Leningradskaya Oblast
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Moskva
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Murmanskaya Oblast
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Nizhegorodskaya Oblast
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Omskaya Oblast
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Sankt-Peterburg
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Yaroslavskaya Oblast
Country [120] 0 0
Spain
State/province [120] 0 0
Barcelona
Country [121] 0 0
Spain
State/province [121] 0 0
La Coruna
Country [122] 0 0
Spain
State/province [122] 0 0
Madrid, Comunidad De
Country [123] 0 0
Spain
State/province [123] 0 0
Badajoz
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Taiwan
State/province [125] 0 0
Kaohsiung
Country [126] 0 0
Taiwan
State/province [126] 0 0
Taichung
Country [127] 0 0
Taiwan
State/province [127] 0 0
Tainan
Country [128] 0 0
Taiwan
State/province [128] 0 0
Taipei
Country [129] 0 0
Turkey
State/province [129] 0 0
Adana
Country [130] 0 0
Turkey
State/province [130] 0 0
Ankara
Country [131] 0 0
Turkey
State/province [131] 0 0
Antalya
Country [132] 0 0
Turkey
State/province [132] 0 0
Istanbul
Country [133] 0 0
Turkey
State/province [133] 0 0
Izmir
Country [134] 0 0
Turkey
State/province [134] 0 0
Konya
Country [135] 0 0
Turkey
State/province [135] 0 0
Sakarya
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Derbyshire
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Essex
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Hertfordshire
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Kent
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Lancashire
Country [141] 0 0
United Kingdom
State/province [141] 0 0
London, City Of
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Nottingham
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Plymouth
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Stoke-on-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Eisai Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) =10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC).

The primary hypotheses for this study are that:

1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and
2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS).

With Amendment 3 (effective: September \[Sep\]-24-2021) participants discontinued lenvatinib and placebo; participants who remained on treatment in the study arms received open-label pembrolizumab.

With Amendment 3 the external Data Monitoring Committee was discontinued.

With Amendment 4 (effective: December-5-2022) Second Course will no longer be offered. Any participant receiving Second Course treatment prior to initiation of Amendment 4 will be able to complete treatment as planned.

With Amendment 4 study participation will end after the final administration of pembrolizumab. Participants who either complete 35 administrations of pembrolizumab or discontinue pembrolizumab will discontinue from the study following the safety follow-up visit. AEs and spontaneously reported pregnancies will be reported and followed per protocol. All participants in efficacy follow-up prior to initiation of Amendment 4 will stop efficacy assessments and be discontinued from the study. All participants in survival follow-up prior to initiation of Amendment 4 are considered to have completed the study and should have a final survival contact. The overall study ends when the last participant completes the last study-related contact or visit, withdraws from the study, or is lost to follow-up.
Trial website
https://clinicaltrials.gov/study/NCT03898180
Trial related presentations / publications
Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Eur Urol. 2024 Mar;85(3):229-238. doi: 10.1016/j.eururo.2023.08.012. Epub 2023 Sep 29.
Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03898180